CNX-2006

Overview

CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cardiovascular and blood system | EGFR

Product Information

• Catalog No.: B0084-462328
• CAS No.: 1375465-09-0
• Molecular Formula: C26H27F4N7O2
• Molecular Weight: 545.543
• Purity: 98%

Source

Original product source